Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBT (2017 - 2025)

Aclaris Therapeutics has reported EBT over the past 9 years, most recently at -$21.1 million for Q4 2025.

  • Quarterly results put EBT at -$21.1 million for Q4 2025, up 78.37% from a year ago — trailing twelve months through Dec 2025 was -$68.7 million (up 48.69% YoY), and the annual figure for FY2025 was -$68.7 million, up 47.95%.
  • EBT for Q4 2025 was -$21.1 million at Aclaris Therapeutics, down from -$15.3 million in the prior quarter.
  • Over the last five years, EBT for ACRS hit a ceiling of -$1.9 million in Q4 2023 and a floor of -$97.6 million in Q4 2024.
  • Median EBT over the past 5 years was -$20.6 million (2021), compared with a mean of -$23.8 million.
  • Biggest five-year swings in EBT: skyrocketed 93.61% in 2023 and later plummeted 5151.45% in 2024.
  • Aclaris Therapeutics' EBT stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then skyrocketed by 93.61% to -$1.9 million in 2023, then plummeted by 5151.45% to -$97.6 million in 2024, then soared by 78.37% to -$21.1 million in 2025.
  • The last three reported values for EBT were -$21.1 million (Q4 2025), -$15.3 million (Q3 2025), and -$16.4 million (Q2 2025) per Business Quant data.